Entrada Therapeutics Inc expected to post a loss of 17 cents a share - Earnings Preview

Entrada Therapeutics

04/03/2024 12:03

* Entrada Therapeutics Inc  TRDA.OQ   TRDA.O  is expected
to show
a rise in quarterly revenue when it reports  results on March 6
(estimated) for the period ending December 31 2023
    * The Boston Massachusetts-based  company is expected to
report
revenue of $23.695 million, according to the mean estimate from
5 analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Entrada Therapeutics Inc
is
for a loss of 17 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Entrada
Therapeutics Inc is $21.00​, above​ its last closing price
of $13.73. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.76       -0.74      1.02      Beat    238.6
 Jun. 30 2023  -0.68       -0.69      -0.78     Missed  -13
 Mar. 31 2023  0.90        0.97       -0.21     Missed  -121.7
                                                        ​
 Dec. 31 2022  -0.83       -0.83      -0.79     Beat    4.4
 ​​Sep.        -0.75       -0.76      -0.80     Missed  -5.3
 30 2022                                                
 Jun. 30 2022  -0.72       -0.72      -0.74     Missed  -2.2​
 Mar. 31 2022  -0.65       -0.65      -0.69     Missed  -5.3
 Dec. 31 2021  -1.29       -1.28      -0.89     Beat    30.7
 This summary was machine generated March 4 at 12:02 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)